Glucose utilization during exercise in normal and diabetic subjects. The role of insulin. 1981

G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006885 Hydroxybutyrates Salts and esters of hydroxybutyric acid. Hydroxybutyric Acid Derivatives,Hydroxybutyric Acids,Acid Derivatives, Hydroxybutyric

Related Publications

G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
January 1990, Journees annuelles de diabetologie de l'Hotel-Dieu,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
January 1997, Canadian journal of physiology and pharmacology,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
January 1959, Diabetes,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
May 1984, Diabetes,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
February 1988, Diabetes/metabolism reviews,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
February 2010, Computer methods and programs in biomedicine,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
October 1974, The Tohoku journal of experimental medicine,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
July 1987, Diabetes research (Edinburgh, Scotland),
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
February 1973, Diabetes,
G Krzentowski, and F Pirnay, and N Pallikarakis, and A S Luyckx, and M Lacroix, and F Mosora, and P J Lefèbvre
September 1976, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!